An overview of chronic lymphocytic leukaemia biology

Best Practice & Research. Clinical Haematology
Maria Teresa Sabrina BertilaccioFederico Caligaris-Cappio

Abstract

Chronic lymphocytic leukaemia (CLL) is characterised by accumulation of CD5(+) monoclonal B cells in primary and secondary lymphoid tissues. Genetic defects and stimuli originating from the microenvironment concur to the selection and expansion of the malignant clone. Several lines of evidence, including molecular and functional analysis of the monoclonal immunoglobulin, support the hypothesis that stimulation through the B-cell receptor affects life and death of leukaemic cells. The microenvironment also has a critical role in the survival and accumulation of leukaemic cells within lymphoid organs where signals delivered from the surrounding cells are likely crucial in inducing proliferation. Nevertheless, several major biological issues still remain to be solved including regulation of the balance between proliferation and survival of leukaemic cells and the links between emerging gene abnormalities and microenvironment. In this context, mouse models are helpful tools in understanding disease mechanisms and in evaluating the efficacy of novel therapeutic agents.

References

Dec 21, 1989·Nature·Y J LiuI C MacLennan
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·A M StallL A Herzenberg
Feb 1, 1982·The Journal of Experimental Medicine·F Caligaris-CappioG Janossy
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·H H WortisD C Parker
Apr 1, 1993·The Journal of Experimental Medicine·E A Ranheim, T J Kipps
Nov 1, 1996·Leukemia & Lymphoma·K SchuhC Kneitz
May 1, 1997·British Journal of Haematology·D WangM J Robertson
Jun 24, 1999·Immunology Today·P YouinouP M Lydyard
Aug 7, 2001·Reviews in Clinical and Experimental Hematology·S StilgenbauerH Döhner
May 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·Roberta BichiCarlo M Croce
Jun 19, 2002·The Journal of Biological Chemistry·Siew-Cheng WongKong-Peng Lam
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Nov 18, 2003·British Journal of Haematology·Federico Caligaris-Cappio
Feb 14, 2004·Blood·Freda K Stevenson, Federico Caligaris-Cappio
Mar 26, 2004·Nature Reviews. Immunology·Miguel Vicente-Manzanares, Francisco Sánchez-Madrid
Aug 18, 2004·The Journal of Experimental Medicine·Bradley T MessmerNicholas Chiorazzi
Aug 25, 2004·Hematology/oncology Clinics of North America·Stephan Stilgenbauer, Hartmut Döhner
Oct 19, 2004·Cancer Cell·Lourdes PlanellesMichael Hahne
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antonia RodríguezMiguel A Piris
Nov 17, 2004·Proceedings of the National Academy of Sciences of the United States of America·Juan M ZapataJohn C Reed
Jan 15, 2005·The Journal of Clinical Investigation·Antonella ContriArianna Donella-Deana
Feb 16, 2005·The Journal of Clinical Investigation·Bradley T MessmerNicholas Chiorazzi
Jun 3, 2005·The Journal of Clinical Investigation·Cristina ScielzoFederico Caligaris-Cappio
Sep 15, 2005·The Journal of Biological Chemistry·Jian-Jiang HaoXi Zhan
Sep 17, 2005·Proceedings of the National Academy of Sciences of the United States of America·Amelia CimminoCarlo M Croce
Oct 4, 2005·Nature Immunology·Stephen B GauldJohn C Cambier
Nov 2, 2005·The Journal of Experimental Medicine·Christina M LauAnn Marshak-Rothstein
Feb 8, 2006·Annals of the New York Academy of Sciences·Nicholas ChiorazziEmilia Albesiano

❮ Previous
Next ❯

Citations

Apr 9, 2013·Hematology/oncology Clinics of North America·Lydia ScarfòPaolo Ghia
Dec 2, 2010·International Journal of Cancer. Journal International Du Cancer·Lingzhi ZhangPaul A Insel
May 11, 2012·British Journal of Haematology·Christine E GillingShantaram S Joshi
Sep 22, 2018·Critical Reviews in Clinical Laboratory Sciences·Ancuta JurjIoana Berindan-Neagoe
Apr 11, 2019·Expert Opinion on Drug Metabolism & Toxicology·Anna Korycka-WolowiecTadeusz Robak
Oct 19, 2011·Cardiovascular and Interventional Radiology·A Ross Naylor
Sep 9, 2017·Oncotarget·Frédéric BoissardMary Poupot
Dec 7, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Elizabeth M Sagatys, Ling Zhang
Feb 11, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Carlo ViscoAgostino Cortelezzi

❮ Previous
Next ❯

Related Concepts

Related Feeds

B cell Activation

B cell activation is initiated by the ligation of the B cell receptor with antigen and ultimately results in the production of protective antibodies against potentially pathogenic invaders. Here is the latest research.

BCL-2 Family Proteins

BLC-2 family proteins are a group that share the same homologous BH domain. They play many different roles including pro-survival signals, mitochondria-mediated apoptosis and removal or damaged cells. They are often regulated by phosphorylation, affecting their catalytic activity. Here is the latest research on BCL-2 family proteins.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.